Funds and ETFs Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 15:44:58 2024-06-17 EDT 5-day change 1st Jan Change
138.4 USD -1.13% Intraday chart for Moderna, Inc. -6.66% +39.46%

ETFs positioned on Moderna, Inc.

Name Weight AuM 1st Jan change Investor Rating
5.66% 0 M€ 0.00% -
4.69% 2 M€ -.--%
4.08% 0 M€ 0.00% -
2.50% 1 M€ +0.84% -
2.40% 21 M€ +8.51% -
2.08% 7 M€ -.--% -
1.81% 7 M€ +4.47%
1.36% 9 M€ -4.31% -
1.21% 1 M€ +2.21% -
0.90% 1,060 M€ +5.64%
0.81% 1 M€ 0.00% -
0.72% 2 M€ +9.20%
0.63% 3 M€ 0.00% -
0.60% 9 M€ -.--% -
0.55% 5 M€ -72.95% -
0.45% 20 M€ 0.00% -
0.34% 38 M€ -.--%
0.30% 23 M€ +14.59%
0.22% 391 M€ +29.80% -
0.21% 8 M€ +4.18% -
0.21% 31 M€ -0.81% -
0.21% 20 M€ +4.20% -
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140 USD
Average target price
145.2 USD
Spread / Average Target
+3.67%
Consensus
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. Funds and ETFs Moderna, Inc.